General Information of Drug (ID: DMKYB4D)

Drug Name
4-((+/-)-(1H-imidazol-1-yl)-(E)-retinoic acid Drug Info
Synonyms
CHEMBL57765; 4-((+/-)-(1H-imidazol-1-yl)-(E)-retinoic acid; SCHEMBL1234027; 4-(1-Imidazolyl)retinoic acid; BDBM50091698; (2E,4E,6E,8E)-9-(3-Imidazol-1-yl-2,6,6-trimethyl-cyclohex-1-enyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9951075
TTD Drug ID
DMKYB4D

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LIAROZOLE DM4OYXE Dermatological disease DA24.Y Phase 2/3 [2]
Rambazole DMP2DNS Psoriasis vulgaris EA90 Phase 2 [3]
4-((+/-)-(1H-imidazol-1-yl)-(E)-methylretinoate DMI15VQ Discovery agent N.A. Investigative [1]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cytochrome P450 26 (CYP26A1) TTD7Q0R CP26A_HUMAN Inhibitor [1]

References

1 Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and pros... J Med Chem. 2004 Dec 30;47(27):6716-29.
2 Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells. Bioorg Med Chem. 2008 Sep 1;16(17):8301-13.
3 Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.